Search Results

You are looking at 91 - 100 of 840 items for :

  • "radiation therapy" x
  • Refine by Access: All x
Clear All
Full access

Anisley Valenciaga, O. Hans Iwenofu, and Gabriel Tinoco

image of MRI showing hypointense large soft tissue mass (3.1 × 5.3 × 5.0 cm) in the right neck (yellow arrow) while patient was receiving pazopanib prior to radiation therapy. Following radiation, the patient experienced considerable pain in her

Full access

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Patrick Yung Wen, Nicole R. McMillian, and Maria Ho

evident on MRI scans. The presenting signs and symptoms of metastatic brain lesions are similar to those of other mass lesions in the brain, such as headache, seizures, and neurologic impairment. Historically, whole-brain radiation therapy (WBRT) and

Full access

James L. Mohler

. ADT Plus Radiation Therapy Does radiation therapy (RT) make ADT more effective, and does ADT improve RT? In the phase III EORTC 22991 trial involving 819 patients, 3 the addition of short-term ADT to RT improved biochemical and clinical disease

Full access

Joachim Yahalom

. Radiation therapy in the treatment of Hodgkin's disease: do you see what I see? J Natl Cancer Inst 2003 ; 95 : 928 – 929 . 3. Longo DL . Hodgkin disease: the sword of Damocles resheathed . Blood 2003 ; 104 : 3418 . 4. Longo DL

Full access

NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021

Featured Updates to the NCCN Guidelines

Margaret von Mehren, John M. Kane III, Marilyn M. Bui, Edwin Choy, Mary Connelly, Sarah Dry, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, Jade Homsi, Vicki Keedy, Ciara M. Kelly, Edward Kim, David Liebner, Martin McCarter, Sean V. McGarry, Christian Meyer, Alberto S. Pappo, Amanda M. Parkes, I. Benjamin Paz, Ivy A. Petersen, Matthew Poppe, Richard F. Riedel, Brian Rubin, Scott Schuetze, Jacob Shabason, Jason K. Sicklick, Matthew B. Spraker, Melissa Zimel, Mary Anne Bergman, and Giby V. George

significant symptoms, intervention is recommended. Treatment options include surgery (if resectable), systemic therapy, definitive radiation therapy (RT), ablation procedures, or surgery with RT. Choice of therapy is dependent upon the anatomic location (ie

Full access

Gary L. Gallia, Steven Brem, and Henry Brem

Schoenfeld D . Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study

Full access

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Brian C. Baumann, Jeremy Bordeaux, Pei-Ling Chen, Robert Chin, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Roy C. Grekin, Kelly Harms, Alan L. Ho, Ashley Holder, John Nicholas Lukens, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Soo Park, Tejesh Patel, Igor Puzanov, Jeffrey Scott, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, William Stebbins, Valencia Thomas, Yaohui G. Xu, Beth McCullough, Mary A. Dwyer, and Mai Q. Nguyen

rates of recurrence (6.8%–32.3%) in studies that occasionally include basal cell carcinoma as well as treatment with radiation therapy (RT). 23 – 28 Risk factors associated with metastasis after Mohs include size >2 cm, Clark level (metastatic CSCC are

Full access

Craig Brown, Sharon Ben-Or, Paul Walker, and Mark Bowling

the main foci of therapy is stereotactic body radiation therapy (SBRT), which uses fiducial markers to track the movement of the lung during the respiratory cycle, minimizing the damage to normal tissue as high doses of radiation are applied to the

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The need for and selection of various local or systemic therapies are based on several

Full access

Presenters: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop

A wide range of approaches exist for treating aggressive nonmelanoma skin cancers, including surgery, radiation therapy (RT), cytotoxic chemotherapy, systemic immunotherapy, and active surveillance. Selecting an appropriate therapeutic approach